Witjes WP - Search Results

1

Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trial.

Colombel M, Heidenreich A, Martínez-Piñeiro L, Babjuk M, Korneyev I, Surcel C, Yakovlev P, Colombo R, Radziszewski P, Witjes F, Schipper R, Mulders P, Witjes WP. Colombel M, et al. Among authors: witjes wp, witjes f. Eur Urol. 2014 Mar;65(3):509-11. doi: 10.1016/j.eururo.2013.10.056. Epub 2013 Nov 11. Eur Urol. 2014. PMID: 24268503

2

The value of neoadjuvant therapy in localized prostate cancer.

Witjes WP, Oosterhof GO, Schaafsma HE, Debruyne FM. Witjes WP, et al. Int J Urol. 1995 Mar;2(1):1-5. doi: 10.1111/j.1442-2042.1995.tb00611.x. Int J Urol. 1995. PMID: 7614403 Free article. Review. No abstract available.

3

Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.

van Gils-Gielen RJ, Witjes WP, Caris CT, Debruyne FM, Witjes JA, Oosterhof GO. van Gils-Gielen RJ, et al. Among authors: witjes wp, witjes ja. Urology. 1995 Apr;45(4):581-6. doi: 10.1016/s0090-4295(99)80047-8. Urology. 1995. PMID: 7716838 Clinical Trial.

4

A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment.

Debruyne FM, Witjes WP, Schulman CC, van Cangh PJ, Oosterhof GO. Debruyne FM, et al. Among authors: witjes wp. Eur Urol. 1994;26 Suppl 1:4. doi: 10.1159/000475423. Eur Urol. 1994. PMID: 7737257 Clinical Trial. No abstract available.

5

Overview of current status of total androgen deprivation in metastasized prostate cancer.

Debruyne FM, Witjes WP. Debruyne FM, et al. Among authors: witjes wp. Eur Urol. 1993;24 Suppl 2:67-71. Eur Urol. 1993. PMID: 8262129 Review.

6

Neoadjuvant therapy in prostate cancer--is it of any use?

Witjes WP, Horenblas S, Oosterhof GO, Schaafsma HE, Debruyne FM. Witjes WP, et al. Eur Urol. 1993;24(4):433-7. doi: 10.1159/000474346. Eur Urol. 1993. PMID: 8287884 Review.

7

Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.

Witjes WP, Rosier FW, de Wildt MJ, van Iersel MP, Debruyne FM, de La Rosette JJ. Witjes WP, et al. J Urol. 1996 Apr;155(4):1317-23. J Urol. 1996. PMID: 8632523 Clinical Trial.

8

Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement.

Witjes WP, de Wildt MJ, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ. Witjes WP, et al. J Urol. 1996 Sep;156(3):1026-34. J Urol. 1996. PMID: 8709301

9

Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.

Witjes WP, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ. Witjes WP, et al. Urology. 1997 Feb;49(2):197-205; discussion 205-6. doi: 10.1016/S0090-4295(96)00490-6. Urology. 1997. PMID: 9037281 Free article. Clinical Trial.

10

The International Continence Society "Benign Prostatic Hyperplasia" Study: international differences in lower urinary tract symptoms and related bother.

Witjes WP, de la Rosette JJ, Donovan JL, Peters TJ, Abrams P, Kay HE, Höfner K, Kinn AC, Walter S. Witjes WP, et al. J Urol. 1997 Apr;157(4):1295-300. doi: 10.1016/s0022-5347(01)64955-3. J Urol. 1997. PMID: 9120925 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page